Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 19, 2024 (filed on Apr 23, 2024)Insider Name:Saggar RajeevOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,649Price:$13.68
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Schundler RussellOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,060Price:$14.58
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Saggar RajeevOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,525Price:$14.58
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Moomaw ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,585Price:$14.58
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Kaseta MichaelOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,136Price:$14.58
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,360Price:$14.58
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Adair JasonOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,189Price:$14.58
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Adair JasonOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,906Price:--
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Adair JasonOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,906Price:--
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Adair JasonOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-260Price:--
Filings by filing date
-
Apr 19, 2024 (filed on Apr 23, 2024)Insider Name:Saggar RajeevOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,649Price:$13.68
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Schundler RussellOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,060Price:$14.58
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Saggar RajeevOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,525Price:$14.58
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Moomaw ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,585Price:$14.58
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Kaseta MichaelOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,136Price:$14.58
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Jeffs RogerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,360Price:$14.58
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Adair JasonOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,906Price:--
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Adair JasonOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,189Price:$14.58
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Adair JasonOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,906Price:--
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Adair JasonOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-260Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 419 Davis Drive, Suite 100 MORRISVILLE NC 27560 |
Tel: | N/A |
Website: | https://www.liquidia.com |
IR: | See website |
Key People | ||
Roger A. Jeffs Chief Executive Officer, Director | Michael Kaseta Chief Financial Officer, Chief Operating Officer | Russell Schundler General Counsel, Secretary |
Scott Moomaw Chief Commercial Officer | Rajeev Saggar Chief Medical Officer |
Business Overview |
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies. |
Financial Overview |
For the fiscal year ended 31 December 2023, Liquidia Corp revenues increased 10% to $17.5M. Net loss increased 91% to $78.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balanc increase from $17.2M to $40.2M (expense), General and administrative - Balan increase of 51% to $36.9M (expense). |
Employees: | 136 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $947.08M as of Dec 31, 2023 |
Annual revenue (TTM): | $17.49M as of Dec 31, 2023 |
EBITDA (TTM): | -$71.78M as of Dec 31, 2023 |
Net annual income (TTM): | -$78.50M as of Dec 31, 2023 |
Free cash flow (TTM): | -$52.85M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 76,027,776 as of Mar 11, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |